Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

Fluoroaniracetam: Initial Biodistribution and Characterization of a new Brain Imaging Agent

Dustin Osborne, Alan Stuckey, Steve Kennel, David Blevins and Murthy Akula
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1103;
Dustin Osborne
1Graduate School of Medicine, University of Tennessee, Knoxville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Stuckey
1Graduate School of Medicine, University of Tennessee, Knoxville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Kennel
1Graduate School of Medicine, University of Tennessee, Knoxville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Blevins
1Graduate School of Medicine, University of Tennessee, Knoxville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murthy Akula
1Graduate School of Medicine, University of Tennessee, Knoxville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1103

Objectives The racetam family of compounds have been used widely in the treatment of a central nervous system disorders ranging from alzheimer's to schizophrenia. The exact mechanism of action for these GABA derivative compounds is not well understood, however, they are known to bind to cholinergic receptors in the brain and may enable imaging of specific protein receptors and transporters. This work examines initial biodistribution and characteristics of a new fluorinated compound, N-[4-(2'-[18F]fluoroethyloxybenzoyl)]pyrrolidin-2-one (Fluoroaniracetam), for potential use in brain imaging applications.

Methods Fluoroaniracetam was developed and synthesized at the University of Tennessee and is currently under internal patent review. The compound was synthesized in three steps with a yield of nearly 35% and >97% radiochemical purity in our first runs. Healthy mice were dynamically imaged using microPET/CT. On the bed injection of 150 μCi was perfomed with data collection starting 10 seconds prior to injection. Listmode data were collected for 60 minutes and histogrammed into dynamic frames. Data were reconstructed using point spread function modeling with attenuation and scatter correction. Regions of interest were drawn in key organs, including the brain, liver, heart, and lungs. Time activity curves (TACs) were generated to assess biodistribution information.

Results TAC analysis indicates rapid biological clearance from all major organs with activity levels of < 3% in all major organs within 8 minutes. Peak activity in the brain of ~10 %ID/g was observed within 1.5 minutes of injection indicating a strong ability to cross the blood-brain barrier.

Conclusions Initial analyses show fast biological clearance of the compound. Peak brain values were found within 5 minutes with rapid entry into the brain. Further studies are needed to assess the complete biodistribution of this compound and to determine its possible use in brain imaging applications. This work indicates that fluoroaniracetam may be a possible candidate for PET brain imaging.

Research Support This work is funded by departmental funds of the Molecular Imaging and Translational Research Program of the University of Tennessee Graduate School of Medicine.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fluoroaniracetam: Initial Biodistribution and Characterization of a new Brain Imaging Agent
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Fluoroaniracetam: Initial Biodistribution and Characterization of a new Brain Imaging Agent
Dustin Osborne, Alan Stuckey, Steve Kennel, David Blevins, Murthy Akula
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1103;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fluoroaniracetam: Initial Biodistribution and Characterization of a new Brain Imaging Agent
Dustin Osborne, Alan Stuckey, Steve Kennel, David Blevins, Murthy Akula
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1103;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • Relationships between tau, atrophy, regional brain activity and connectivity in Alzheimer's disease: a PET/MRI multimodal study
  • Gray matter structural networks related to 18F-THK5351 retention in cognitively normal older adults and early Alzheimer’s disease patients
  • Assessment of α4β2 nicotinic acetylcholine receptor (nAChR) availability and neuronal response to rewarding food-cues in human obesity using simultaneous PET-MRI
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Special MTA: Preclinical Probes for Neuroimaging Posters

  • Preclinical evaluation of novel PET-tracers for tau imaging
  • Development of Novel PET Imaging Agents for Vesicular Monoamine Transporter Type 2
  • Development of 2-[18F]trifluoromethyl-L-tryptophan (2-[18F]CF3-L-Trp) for serotonergic system imaging
Show more Special MTA: Preclinical Probes for Neuroimaging Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire